| 产品名称 | Quartett C-P001/P-P001 | PD-L1 (QR001) |
|---|---|
| 目录号 | C-P001/P-P001 |
| 别名 | PD-L1 |
| 外观 | 见COA |
| 分子量 | |
| CAS | |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
Quartett C-C031/P-C031 | CD31 (QR034)
品名：PD-L1 (QR001) | Recombinant monoclonal rabbit antibody
货号：C-P001/P-P001
品牌：Quartett
规格：0.1 ml; 0.5 ml; 1 ml; 3 ml; 7 ml; 15 ml
产品描述
| Application | IHC (FFPE) | Host | Rabbit |
| Subclass | IgG | Dilution range | 1:100 – 1:200 |
| Cellular localization | Membrane | Control | Non-small cell lung cancer, tonsil |
| Immunogen | Synthetic peptide from human PD-L1 | ||
PD-L1, also known as CD274 and B7-H1, downregulates T cell activation and immune responses by binding to PD-1, which is expressed by cytotoxic T cells. Many tumors upregulate PD-L1 expression, thus inactivating PD-1-expressing cytotoxic T cells. The activity of cytotoxic T cells can be restored by treatment with anti-PD-1 or anti-PD-L1 antibodies, which disrupt the bond between PD-L1 and PD-1. Detection of PD-L1 expression on tumor cells is a tool for identifying tumor patients who may be suitable for successful checkpoint therapy with anti-PD-1 and/or anti-PD-L1 antibodies. Research studies show that PD-L1 is expressed in various tumor types, including non-small cell lung cancer (NSCLC), malignant melanoma, renal cell carcinoma (RCC), bladder cancer, gastric cancer, colorectal cancer (CRC), pancreatic cancer, triple-negative breast cancer (TNBC), classical Hodgkin lymphoma (CHL), and others. The rabbit monoclonal antibody anti-PD-L1 (QR001) demonstrates consistent performance without any cross-reactivity with PD-L2 and other antigens. Its strong specific staining and sensitivity have been confirmed in various national and international studies and quality assurance circles. The use of LDAs (laboratory-developed assays) such as QR001 for PD-L1 status determination can reduce costs by up to five times without compromising quality compared to companion diagnostics.
